Poxel have shared press release with an update for PXL770 treatment

Poxel is “pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN)”.

To view the full press release (11th April 2022): https://www.newcontact.eu/secure/media/com_newcap/files/files/PXL770%20FTD_ENG_2022%2004%2011%20vFinal.pdf